E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033359 |
E.1.2 | Term | Packed red blood cell transfusion |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We want to study whether duration of storage of packed red blood cells has an effect on pulmonary arterial pressure and pulmonary vascular resistance |
|
E.2.2 | Secondary objectives of the trial |
We want to study whether duration of storage of packed red blood cells has an effect on systemic arterial pressure and pulmonary vascular resistance, as well as cardiac output and free hemoglobin concentrations |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. The patient has a pulmonary artery catheter in place 2. Transfusion of 1 unit of packed red blood cells indicated for standard intensive care therapy 3. The patient has an arterial catheter
|
|
E.4 | Principal exclusion criteria |
1. Age < 18 years 2. Clinical prediction that the patient will not survive at least 48 hours 3. Acute bleeding: > 2 units of PRBCs/hour 4. Vasopressor use: noradrenalin > 0.2 µg/kg/min or any use of adrenalin within 6 hours of inclusion into the study 5. Therapy with inhaled NO, inhaled prostacyclin, or PDE-5-inhibitors 6. Sepsis |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Difference in pulmonary arterial pressure between begin and end of transfusion |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
T=0min (begin of transfusion) and T=15min (end of transfusion) |
|
E.5.2 | Secondary end point(s) |
Difference in pulmonary vascular resistance, systemic arterial pressue, systemic vascular resistance, and cardiac output between begin and end of transfusion. Difference in free hemoglobin concentration between begin and end of transfusion. Correlation between the increase in pulmonary arterial pressure and free hemoglobin at the end of transfusion. Comparison of following lab parameters in both study groups: erythrocytes, hematocrit, hemoglobin, leukocytes, platelets, glucose, creatinine, BUN, GOT, GPT, AP, Na, K, bilirubin. Follow-up of all parameters for an additional 45 min after the end of transfusion. Should the primary end point be positiv we will perform a „Nitric oxide consumption assay“
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
T=0min (begin of transfusion), T=15min (end of transfusion), and T=60min (follow-up) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
fresh packed red blood cells (stored < 14 days) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Inclusion of last study subject (64 total). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |